Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignant tumor after hepatocellular carcinoma (HCC). It represents 10% to 20% of all primary liver malignant tumors, with an estimated 3100 new cases of ICC occurring every year in the United States.
1 A relatively uncommon disease with a poor prognosis for survival, the incidence of ICC has been increasing during the last 3 decades.
2,3 Surgical resection is the mainstay of curative intent treatment for ICC and is associated with improved survival in selected patients.
2,3 We previously published data on a large, multi-institutional, multinational cohort of patients and noted that 5-year survival after surgical resection was 30% to 35%.
3